Alnylam Advances Key Programs to Achieve Profitability Goals

Alnylam Pharmaceuticals has made significant progress in its pipeline, advancing multiple Phase 3 trials, including TRITON-CM for ATTR-CM and TRITON-PN for hATTR-PN. The company aims to achieve sustainable profitability under the P5x25 goals. Alnylam's financial health is characterized by robust revenue growth and a strong balance sheet, with revenue reaching $2.35 billion and a year-over-year growth of 16.5%. The company faces challenges with negative operating and net margins, but maintains a current and quick ratio of 3.04 and 2.98, respectively.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) reported robust financial results for the second quarter ended June 30, 2025, with significant growth in revenue and progress in its pipeline. The company's total net product revenues increased by 64% year-over-year to $672.2 million, driven primarily by the AMVUTTRA® (vutrisiran) franchise, which grew by 77% to $544.4 million [1].

Key highlights of Alnylam's Q2 performance include:

1. Revenue Growth: Total net product revenues reached $672.2 million, representing a 64% increase compared to the same period in 2024. This growth was primarily driven by AMVUTTRA, which saw a 77% increase in revenues to $544.4 million. The company also reported strong growth in its rare disease franchise, with GIVLAARI® (givosiran) and OXLUMO® (lumasiran) revenues increasing by 30% and 15%, respectively [1].

2. Pipeline Advancements: Alnylam continued to advance its pipeline with several key initiatives. The company initiated the TRITON-CM Phase 3 trial of nucresiran in patients with ATTR-CM and received Fast Track Designation from the FDA for this treatment. Additionally, Alnylam plans to initiate the TRITON-PN Phase 3 trial of nucresiran in hATTR-PN and a Phase 3 cardiovascular outcomes trial of zilebesiran in hypertension [1].

3. Regulatory Approvals: Alnylam obtained regulatory approvals for AMVUTTRA in several global markets, including the European Union, Brazil, the United Kingdom, and Japan. This approval expands the market access for AMVUTTRA and supports the company's goal of delivering transformational innovation to patients [1].

4. Financial Health: Despite the strong revenue growth, Alnylam faced challenges with negative operating and net margins. However, the company maintains a strong balance sheet, with a current ratio of 3.04 and a quick ratio of 2.98, indicating robust liquidity [1].

Alnylam's financial health and pipeline advancements position the company well to achieve its P5x25 goals and deliver sustainable profitability. The company's focus on innovation and patient access is evident in its progress and future plans, which include additional trials and market expansions.

References:
[1] https://investors.alnylam.com/press-release?id=29136